Persistent viral infections pose a unique challenge to the immune system. Prolonged antigen exposure drives T cells into a state of exhaustion — a ...

Progress against cancer doesn’t always arrive as headlines. Often, it shows up quietly in longer lives, better tolerability, and higher expectations for what treatment can deliver. The fight against ...

Addition of VENCLYXTO plus acalabrutinib, with or without obinutuzumab, and VENCLYXTO plus ibrutinib supported by data from Phase 3 AMPLIFY trial, Phase 3 GLOW trial and Phase 2 CAPTIVATE trial ...

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of ...

A New Hampshire woman says she is alive today thanks to life-saving blood transfusions made possible by blood donations.

A New Castle woman was told she had chronic lymphocytic leukemia, a slow-growing blood cancer that affects a person's white ...

Researchers review available clinical evidence for retreatment with venetoclax, alone or in combination, in patients with relapsed chronic lymphocytic leukemia.

Researchers sought to compare the safety and effectiveness of zanubrutinib and ibrutinib in routine clinical practice.

Treatment with so-called BTK inhibitors has improved the prognosis for people with chronic lymphocytic leukemia (CLL). At the same time, these drugs affect the immune system and may cause side effects ...

Six-year Sequoia data show zanubrutinib in frontline CLL extends PFS far beyond bendamustine‑rituximab, delaying next ...

IntroductionBruton’s tyrosine kinase (BTK) is at the core of present day treatment in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) which in turn is redefining first line and ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical ...